RESEARCH ARTICLE

Characterization of Carbapenem-Resistant Enterobacteriaceae with High Rate of Autochthonous Transmission in the Arabian Peninsula

Ágnes Sonnevend¹, Akela A. Ghazawi¹, Rayhan Hashmey², Wafaa Jamal³, Vincent O. Rotimi³, Atef M. Shibli⁴,⁵, Amina Al-Jardani⁶, Seif S. Al-Abri⁷, Waheed U. Z. Tariq⁸, Stefan Weber⁹, Tibor Pál¹

¹ Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, ² Department of Medicine, Tawam Hospital, Al Ain, United Arab Emirates, ³ Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait, ⁴ Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia, ⁵ Department of Pathology and Pharmacology, College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia, ⁶ Central Public Health Laboratories, Ministry of Health, Muscat, Oman, ⁷ Department of Medicine, Royal Hospital, Muscat, Sultanate of Oman, ⁸ Department of Laboratory Medicine, Tawam Hospital, Al Ain, United Arab Emirates, ⁹ Department of Pathology and Laboratory Medicine, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

*tpal@uaeu.ac.ae

Abstract

To establish the role of local transmission versus possible pathogen import due to previous foreign exposure in infections caused by carbapenem non-susceptible Enterobacteriaceae in the Arabian Peninsula, 200 independent isolates collected in 16 hospitals of Saudi Arabia, Kuwait, Oman and the United Arab Emirates were studied. All strains were multidrug resistant; 42.5% of them also qualified as extremely drug resistant. The frequency of various carbapenemases varied according to the participating countries, but in the collection, as a whole, blaNDM-1 was the most frequently encountered carbapenemase gene (46.5%) followed by blaOXA-48-like gene (32.5%). A comparatively high rate (8.9%) of multi-clonal strains carrying both blaNDM and blaOXA-48-like genes in the United Arab Emirates, representing the most resistant subgroup, was encountered. No KPC-expressing isolates were detected. Three major clones of blaNDM-1 carrying Klebsiella pneumoniae of ST152 (n = 22, Saudi Arabia), ST14 (n = 7, United Arab Emirates) and ST147 types (n = 9, Oman) were identified, the latter two clones carrying similar, but not identical HI1b incompatibility type plasmids of >170kb. While from 78.6% of the cases with documented foreign hospitalization blaNDM positive strains were isolated, these strains formed only 25.6% of all the isolates expressing this enzyme. In fact, 56.8% of the NDM, 75.7% of OXA-48-like and 90.9% of VIM positive strains were recovered from patients without documented foreign exposure, neither in the form of travel or prior hospitalization abroad, suggesting a high rate of autochthonous infections. This, considering the extensive links of these countries to the rest of the world, predicts that trends in the local epidemiology of carbapenem resistant strains may increasingly...
affect the spread of these pathogens on the global scale. These results call for improved surveillance of carbapenem resistant *Enterobacteriaceae* in the countries of the Arabian Peninsula.

**Introduction**

Countries of the Arabian Peninsula have rapidly developing links to the rest of the World as becoming increasingly busy business and medical tourism hubs and some of them popular holiday destinations, as well. A unique feature of their population structure is the high rate of resident expatriates (as an average, approximately 48%), which rate in Qatar and the United Arab Emirates (UAE) reaches more than 80% [1]. The majority of these expatriate workers arrive from the Indian Subcontinent, the Far East, and Africa and from other Middle Eastern countries. They, as well as citizens of the Gulf countries, frequently seek health care abroad in North America, Europe, and in their own home countries, i.e. regions frequently burdened by high rate of antibiotic resistance.

These characteristics make countries of the Arabian Peninsula highly exposed to the spread of various infectious agents, including carbapenem resistant *Enterobacteriaceae* (CRE). Indeed, these strains have been reported from sporadic cases and from small outbreaks in almost all countries of the region [2–18]. Conversely, the extensive international connections are also likely to facilitate the spread of CRE from these countries to other parts of the Globe. This role has been well documented for the broader Middle Eastern region, particularly in case of strains producing OXA-48-like and NDM type carbapenemases [19–21]. Based on a limited number documented cases in Europe and in the USA with links specifically to some of the respective countries, or to their immediate vicinity [19, 22–26], a similar role has been proposed for the Arabian Peninsula, as well [20]. Nonetheless, local information based on systematic antibiotic resistance surveillance is sparse [27]. Even less known are the similarities and differences in the epidemiology of CRE in the different countries of the Peninsula. We are aware of one study, only, with the aim to compare isolates collected from multiple countries of the region, but even in this project over 80% of the carbapenemase producing strains among the total of 62 CRE isolates studied were isolated in a single Saudi hospital [17].

From the extensive exposure of these countries one may predict that a considerable part of local CRE cases could actually be imported. However, there are no local surveillance data either to support or to oppose such predictions. A limited number of CRE infections with no previous foreign exposure were indeed documented in the region [4, 5, 7, 9, 11, 12, 28, 29]. However the actual rate of such events, suggestive of autochthonous transmission, compared to those with proven prior foreign exposure is not known. Such information is important to understand the local epidemiology of CRE and to establish local screening strategies for these pathogens when admitting patients to hospitals. Here we present our data on the distribution of various types of carbapenemases, on the antibiotic susceptibility, genotype, clustering, and travel-, and prior hospitalization-related nature of 200 independent, carbapenem non-susceptible *Enterobacteriaceae* isolates recovered in four countries of the Arabian Peninsula.

**Materials and Methods**

**Strains and data collection**

Altogether 265 non-repeat *Enterobacteriaceae* strains isolated between April 2009 and April 2013 from inpatients of 16 hospitals of the Kingdom of Saudi Arabia, (KSA), Kuwait, Oman
and the UAE were submitted to the Department of Medical Microbiology and Immunology, UAE University. For comparison, this pool of strains included 6 *Klebsiella pneumoniae* (KKP1, 2, 4, 6, 8, 11), 1 *Escherichia coli* (KEC7) and 1 *Enterobacter cloacae* (KECL3) expressing VIM-4, and 2 NDM positive *K. pneumoniae* (KKP5 and 9) from Kuwait, and 6 NDM positive (strains No.1, 2, 4, 6, 13, 15), 1 OXA-48-like-positive *K. pneumoniae* (strain No.11) and 1 OXA-48-like-positive *E. coli* (strain No.3) strains from Oman that had been parts of collections studied earlier [4, 9]. All strains were isolated by clinical or epidemiological indications, and not for the purpose of the current study. The only initial criteria for an *Enterobacteriaceae* isolate to qualify for submission was that at the time of its isolation the strain exhibited decreased susceptibility to any of the carbapenems, by any methods used by the respective laboratories. After re-testing at UAE University (see later), strains with confirmed non-susceptibility by the CLSI criteria (30) to at least one of the carbapenems used (i.e. imipenem, meropenem, ertapenem) were finally included in the study. Strains were stored in duplicates at -80°C in Tryptic Soy broth (MAST Group Ltd., UK) containing 20% glycerol.

Data on age, gender, sample type, and the clinical relevance of the isolate, as assessed by the providing laboratories, along with history of travel and hospitalization within one-year prior the isolation of the strains were obtained by local participants of the project from databases complementing the strain collections of the respective laboratories. The absence of relevant data was specifically noted. For the KSA isolates, only the fact of previous hospitalization, but not its actual location was known, hence these cases were not used in the respective analyses. Access to records on nationality, clinical diagnosis, treatment and clinical outcome were limited, hence the effect of these factors was not addressed within the current study.

**Phenotypic tests**

Susceptibility to ampicillin, amoxicillin-clavulanic acid, cefoxitin, piperacillin-tazobactam, cefpodoxime, ciprofloxacin, gentamicin, tobramycin, amikacin, chloramphenicol, doxycycline and trimethoprim-sulfamethoxazole was tested by disc diffusion. The Minimum Inhibitory Concentration (MIC) to ceftazidime, cefotaxime, aztreonam, imipenem, meropenem, ertapenem was determined by microdilution according to CLSI [30] using *Escherichia coli* ATCC25922 as control. Tigecycline and colistin sensitivity was assessed by Etest (bioMérieux, US) applying the EUCAST guidelines [31]. To compare susceptibilities of various groups of strains, the MIC$_90$ and MIC$_50$ values were used. Strains were considered as multi-, or extensively drug resistant (MDR and XDR, respectively) according to the recent recommendations [32]. The carbapenemase production of the strains was assessed by the CarbaNP test [33].

**Molecular methods**

The presence of the *bla$_{NDM}$*, *bla$_{OXA-48}$*, *bla$_{VIM}$*, *bla$_{IMP}$*, *bla$_{KPC}$* carbapenemase genes, and armA, rmtA, B, C and D ribosomal methylase genes were tested by PCR [7, 34]. Sequences of the entire *bla$_{NDM}$* [7] and *bla$_{VIM}$* [8] genes, and that of a 708 bp internal part of the *bla$_{OXA-48}$* gene characteristic to the most common alleles [35, 36] were determined. Plasmids carrying carbapenemase genes were conjugally transferred into a Na-azide resistant derivative of *E. coli* J53 and their molecular mass, incompatibility type and RFLP was determined, as previously described [7].

Macrorestriction patterns of *Xba*1-digested genomic DNA obtained by pulsed field gel electrophoresis (PFGE) were compared using the GelCompar II software (Applied Maths, Belgium) [7]. A clone was tentatively defined as a PFGE cluster of the same species isolates with $\geq$ 80% similarity, expressing the same carbapenemase and harboring carbapenemase gene-carrying plasmids of the same molecular mass and, if typable, of the same incompatibility group.
The multi-locus sequence type (MLST) of selected *K. pneumoniae* strains was also determined [37].

**Statistical analysis**

Fisher’s exact test (two tailed) was used to compare variables of different groups of strains.

**Ethics statement**

The study did not make use of human or vertebrate animal subjects or tissues. The bacterial isolates studied were obtained from existing strain collections routinely assembled as part of clinical laboratory practices saving multi-drug resistant organisms and no specimens were collected for the purpose of this study. Strains studied were accompanied by data only that did not allow any patient identification (i.e. no names, birth dates, personal-, hospital-, or laboratory identification numbers were known) and the data were analyzed anonymously. Collection of the strains in each of the participating clinical laboratories was conducted in accordance with the Declaration of Helsinki and with the particular institutional ethical and professional standards.

**Results**

**The collection**

After confirming their carbapenem non-susceptibility, altogether 200 non-repeat strains were included in the study. One hundred and seventy of the isolates (85.0%) were judged clinically relevant by the clinical microbiologists of the submitting laboratories. The details of the strains, patients, specimens and the list of providing hospitals according to the participating countries are shown in Table 1.

| Table 1. Distribution of the isolates, patients, specimen types and hospitals among the participating countries. |
|---------------------------------------------------------------|
| **The isolates (N)** | **All** | **KSA** | **Kuwait** | **Oman** | **UAE** |
|----------------------|---------|---------|-----------|---------|---------|
| *K. pneumoniae*       | 145     | 46      | 17        | 41      | 41      |
| *E. coli*             | 28      | 3       | 5         | 10      | 10      |
| *E. cloacae*          | 17      | 4       | 3         | 7       | 3       |
| Others               | 10      | 1       | 2         | 5       | 2       |
| **The patients**      |         |         |           |         |         |
| Age in years (x±sd)   | 53.2 ± 22.0 | 57.1 ± 12.9 | 54.7 ± 27.5 | 47.9 ± 24.8 | 55.3 ± 22.6 |
| Male:female ratio     | 1.8     | 3.15    | 0.92      | 1.42    | 2.16    |
| **The specimens (%)** |         |         |           |         |         |
| Respiratory          | 29.5    | 70.4    | 0.0       | 11.1    | 25.0    |
| Blood                | 15.5    | 20.4    | 14.8      | 9.5     | 17.9    |
| Pus                  | 19.0    | 1.9     | 25.9      | 39.7    | 8.9     |
| Urine                | 21.0    | 7.4     | 59.3      | 19.0    | 17.9    |
| Screening            | 11.5    | 0.0     | 0.0       | 20.6    | 17.9    |
| Unknown              | 3.5     | 0.0     | 0.0       | 0.0     | 12.5    |
| **The hospitals (N of isolates)** | **A** (22) | **Mubarak** (16) | **Royal** (63) | **Mafraq** (17) |
|----------------------|---------|---------|-----------|---------|
| B                    | (15)    | Adan    | (5)       | Tawarm  | (17)    |
| C                    | (17)    | Amiri   | (3)       | SKMC    | (4)     |
|                       |         | Ibn Sina | (3)      | Zayed   | (2)     |
|                       |         |          |           | Al Ain  | (1)     |
|                       |         |          |           | Quasimi | (12)    |
|                       |         |          |           | Kuwait  | (2)     |
|                       |         |          |           | Dubai City | (1)     |

doi:10.1371/journal.pone.0131372.t001
Beyond K. pneumoniae (72.5%), E. coli (14.0%) and E. cloacae (8.5%). Citrobacter freundii was represented by 3, Morganella morganii and K. oxytoca by 2, and C. koseri, Serratia marscescens and Providencia stuartii by 1 isolates, each, respectively.

Distribution of carbapenemase and other antibiotic resistance genes

The most common single carbapenemase gene encountered was blaNDM carried by 93 (46.5%) of the isolates followed by blaOXA-48-like and blaVIM (Table 2). Neither blaIMP, nor blaKPC carriers were detected. The 23 isolates (11.5%), in which none of the five carbapenemase genes targeted were found, did not exhibit any carbapenemase activity. There were notable differences between countries regarding the frequencies of carbapenemase genes. While in the Saudi, Omani and in the Emirati collections the most common carbapenemase gene detected was the blaNDM followed by the blaOXA-48-like gene, in the Kuwaiti collection blaVIM was the most frequently encountered one. However, once strains previously reported from this country [9] were excluded, none of the remaining 17 Kuwaiti isolates carried this latter gene, and among them the blaOXA-48-like gene (41.2%) was the most frequent one, followed by non-carbapenemase producing isolates (35.2%) and by blaNDM carrying ones (23.5%) (data not shown).

All blaNDM genes detected represented the blaNDM-1 allelic variant with the exception of two E. coli strains (Oman and UAE) carrying the blaNDM-7 allele. Apart from one Emirati K. pneumoniae strain carrying blaOXA-162, the sequences of a 708 bp long internal parts of the blaOXA-48-like genes were consistent with that of the blaOXA-48 allele in all strains producing OXA-type carbapenemase, only. On the other hand, the blaOXA genes of the 7 K. pneumoniae strains also carrying the blaNDM gene exhibited a much higher variability. Their respective 708 bp internal sequences were suggestive of blaOXA-48 (in 1 KSA and 1 UAE isolates), of blaOXA-162 (1 strain from the UAE), of blaOXA-181 (1 Omani strain) and blaOXA-232 in 3 isolates from the UAE, respectively. Similarly to the Kuwaiti strains present in the collection and described earlier [9] all new VIM-positive isolates expressed the VIM-4 allele.

64.5% of all strains with blaNDM, as a single carbapenemase gene, also carried a 16S modifying enzyme gene responsible for aminoglycoside resistance, significantly more frequently (P<0.0001) than those expressing OXA-48-like carbapenemases (13.8%).

The distribution of genes coding for carbapenemases in the three most common species in general, as well as by sample types is shown in Table 3. Altogether, NDM positive K. pneumoniae was the largest sub-group (39.0%) in the entire collection. In the mixed species group, the

---

Table 2. Frequencies of different resistance genes among the isolates.

| Resistance classes | Resistance gene | Entire collection (%*) (N = 200) | KSA (N = 54) | Kuwait (N = 27) | Oman (N = 63) | UAE (N = 56) |
|--------------------|----------------|---------------------------------|-------------|----------------|-------------|-------------|
| Carbapenemases     | blaNDM         | 46.5                            | 57.4        | 22.2           | 46.0        | 48.2        |
|                    | blaOXA48-like  | 32.5                            | 33.3        | 25.9           | 44.4        | 21.4        |
|                    | blaNDM + blaOXA48-like | 3.5 | 1.9 | 0.0 | 1.6 | 8.9 |
|                    | blaVIM         | 6.0                             | 1.9         | 29.6           | 3.2         | 1.8         |
|                    | No carbapenemase gene | 11.5 | 5.6 | 22.2 | 4.8 | 19.6 |
| Ribosome-modifying enzymes | armA | 15.5 | 11.1 | 0.0 | 23.8 | 17.9 |
|                    | rmtB           | 0.5                             | 0.0         | 0.0            | 1.6         | 0.0         |
|                    | rmtC           | 21.5                            | 57.4        | 14.8           | 11.1        | 1.8         |

* % calculated in the entire collection
& % calculated in the respective collections of specific countries

doi:10.1371/journal.pone.0131372.t002
OXA-48-like gene was present in 2 *K. oxytoca*, and in 1 *C. freundii*, *C. koseri* and *S. marcescens* strains, while 2 *C. freundii* and 2 *M. morganii* strains were blaNDM positive. One *P. stuartii* strain did not carry any of the carbapenemase genes targeted.

blaOXA-48-like positive *K. pneumoniae* were recovered from blood samples significantly less frequently than other species expressing the same enzyme (P = 0.0043), or the same species with other carbapenemases (P = 0.0349). No further, statistically significant correlation between the species or resistance mechanism and the site of infection could be established.

**Antibiotic susceptibility**

All isolates scored at least of multi-drug resistant (MDR) [32], while 42.5% of them also fulfilled the criteria for extremely drug resistant (XDR) with rates considerably varying between the countries (Table 4). Strains carrying both blaNDM and blaOXA-48-like genes were the most, and those expressing OXA-48-like carbapenemase alone were the least likely to be XDR. Only six strains in the entire collection exhibited decreased susceptibility to both tigecycline and colistin, representing all participating countries at least by one isolate. Beyond these two agents, amikacin and chloramphenicol were the most active antibiotics with 50.5% and 54.0% non-susceptibility rates, respectively (data not shown).

**Clonality of the isolates**

Of all the *K. pneumoniae*, *E. coli* and *E. cloacae* strains subjected to genomic restriction digestion 5 strains (3 NDM-expressing *E. coli*, 1 *K. pneumoniae* carrying the blaOXA48-like gene, and 1 without carbapenemases, respectively) were non-typable. With the exception of two duplets among *E. coli* and two triplets among *E. cloacae* no clustering was observed among strains of

---

**Table 3. Distribution of carbapenem resistance mechanisms in isolates recovered from various specimen.**

| Species               | Carbapenemase produced | % in  |  |  |  |  |  |
|-----------------------|------------------------|-------|---|---|---|---|---|
|                       |                        | All specimens | Respiratory | Blood | Urine | Pus | Unknown | Screening |
| All (N = 200)         | NDM                    | 46.5   | 54.2 | 38.7 | 42.9 | 47.4 | 14.3 | 52.2   |
|                       | OXA                    | 32.5   | 33.9 | 29.0 | 31.0 | 39.5 | 14.3 | 30.4   |
|                       | NDM-OXA                | 3.5    | 3.4  | 3.2  | 4.8  | 2.6  | 0.0  | 4.3    |
|                       | VIM                    | 6.0    | 1.7  | 12.9 | 9.5  | 7.9  | 0.0  | 0.0    |
|                       | none                   | 11.5   | 6.8  | 16.1 | 11.9 | 2.6  | 71.4 | 13.0   |
| *K. pneumoniae* (N = 145) | NDM                    | 53.8   | 53.8 | 52.4 | 48.1 | 60.0 | 25.0 | 62.5   |
|                       | OXA                    | 29.7   | 36.5 | 9.5  | 37.0 | 28.0 | 25.0 | 25.0   |
|                       | NDM-OXA                | 4.8    | 3.8  | 4.8  | 7.4  | 4.0  | 0.0  | 6.3    |
|                       | VIM                    | 4.1    | 0.0  | 14.3 | 7.4  | 4.0  | 0.0  | 0.0    |
|                       | none                   | 7.6    | 5.8  | 19.0 | 0.0  | 4.0  | 50.0 | 6.3    |
| *E. coli* (N = 28)    | NDM                    | 32.1   | 66.7 | 20.0 | 42.9 | 25.0 | 0.0  | 0.0    |
|                       | OXA                    | 32.1   | 16.7 | 60.0 | 14.3 | 75.0 | 0.0  | 33.3   |
|                       | NDM-OXA                | 0.0    | -    | -    | -    | -    | -    | -      |
|                       | VIM                    | 3.6    | 0.0  | 0.0  | 14.3 | 0.0  | 0.0  | 0.0    |
|                       | none                   | 32.1   | 16.7 | 20.0 | 28.6 | 0.0  | 100.0 | 66.7 |
| *E. cloacae* (N = 17) | NDM                    | 11.8   | 0.0  | 0.0  | 0.0  | 28.6 | 0.0  | 0.0    |
|                       | OXA                    | 47.1   | 0.0  | 75.0 | 25.0 | 42.9 | 0.0  | 100.0  |
|                       | NDM-OXA                | 0.0    | -    | -    | -    | -    | -    | -      |
|                       | VIM                    | 29.4   | 100.0 | 0.0 | 25.0 | 28.6 | 0.0  | 0.0    |
|                       | none                   | 11.8   | 0.0  | 25.0 | 50.0 | 0.0  | 0.0  | 0.0    |

*doi:10.1371/journal.pone.0131372.t003*
these two species. Among the 143 *K. pneumoniae* strains typed, 6 PFGE clusters (1–6) (1 with 4, 2 with 6, 1 with 9, 1 with 10 and 1 with 23 members) were identified (S1–S3 Figs). After excluding clusters 2 and 4 due to the variety of carbapenemases expressed, and cluster 1 due to the variation in plasmid profiles and exhibiting 4 different sizes of pNDMs (data not shown), 3 tentative clones (A–C, Table 5) were identified. All clones expressed *bla* ND M-1 (Table 5). The Omani clone C (n = 9) contained four members previously described (strains No.1, 2, 6 and 15 in [4]) beyond 5 newly encountered ones. Members of the 3 clones together represented 26.2% of all, and 48.7% of the *bla* ND M-1 positive, typable *K. pneumoniae* strains.

The molecular mass and incompatibility type (HI1b) of the NDM plasmids in the Emirati clone B and in the Omani clone C, as assessed after conjugally transferring them to a suitable recipient (S1 Table) were similar (i.e. >170kb) (Table 5). While plasmids in the two Omani isolates yielded RFLP patterns indistinguishable by the naked eye with any of the enzymes (XbaI, BamHI and SmaI) used, their restriction patterns were noticeably different from those of the UAE isolates, which also exhibited differences between each other (S4 Fig).

### Table 4. Antibiotic susceptibility of the strains by country, by resistance mechanism and by species.

| Country | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | MIC<sub>S0</sub> | R (%) | MIC<sub>S0</sub> | MIC<sub>S0</sub> | R (%) | % |
|---------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------|----------------|----------------|-------|---|
| All     | 16             | >64            | 8              | 32             | 32             | 128            | >128           | >128           | 1              | 4              | 22             | 0.19           | 0.38           | 4.1            | 42.5  |
| KSA     | 16             | 64             | 16             | 32             | 32             | 64             | >128           | >128           | 1              | 2              | 7.4            | 0.19           | 0.38           | 7.5            | 18.5  |
| Kuwait  | 16             | 64             | 8              | 128            | 16             | 128            | >128           | >128           | 1              | 4              | 25.9           | 0.25           | 0.38           | 4.0            | 33.3  |
| Oman    | 16             | 64             | 8              | 16             | 16             | 64             | >128           | >128           | 1              | 4              | 27.0           | 0.125          | 0.38           | 3.2            | 46.0  |
| UAE     | 32             | >64            | 8              | 32             | 64             | 128            | >128           | >128           | 1              | 4              | 28.6           | 0.19           | 0.25           | 1.8            | 66.0  |
| Carbapenemase |          |                |                |                |                |                |                |                |                |                |                |                |                |                |       |
| NDM     | 16             | >64            | 8              | 32             | 32             | >128           | >128           | >128           | 1              | 4              | 22.6           | 0.19           | 0.38           | 4.4            | 49.4  |
| OXA-48-like | 8             | 32             | 8              | 32             | 16             | 32             | 128            | >128           | 1              | 4              | 16.9           | 0.19           | 0.38           | 3.1            | 29.2  |
| NDM+OXA | >64            | >64            | 16             | 128            | 128            | >128           | >128           | >128           | 2              | 4              | 50.0           | 0.19           | 0.25           | 0.0            | 71.4  |
| VIM     | 8              | 32             | 8              | 32             | 16             | 128            | 128            | >128           | 1.5            | 5              | 33.3           | 0.125          | 0.25           | 8.3            | 58.3  |
| None    | 64             | >64            | 4              | 8              | 64             | 128            | >128           | >128           | 0.75           | 4              | 21.7           | 0.19           | 0.38           | 9.1            | 34.8  |
| Species |                |                |                |                |                |                |                |                |                |                |                |                |                |                |       |
| *K. pneumoniae* | 16          | >64            | 8              | 32             | 32             | >128           | >128           | >128           | 1.5            | 4              | 26.2           | 0.19           | 0.38           | 4.8            | 46.2  |
| *E. coli* | 16          | >64            | 8              | 16             | 16             | >128           | >128           | >128           | 0.38           | 1              | 0.0            | 0.19           | 0.38           | 3.6            | 21.4  |
| *E. cloacae* | 8           | 32             | 8              | 16             | 16             | >128           | >128           | >128           | 1              | 3              | 17.6           | 0.19           | 0.25           | 0.0            | 41.2  |

ERT—ertapenem, IMI—imipenem, MER—meropenem, CAZ—ceftazidime, TIG—Tigecycline, COL—colistin, XDR—extensively drug resistant

* without *Proteus* and *Morganella*

### Table 5. Characteristics of the major clones encountered.

| Clones | Country | n | Hospital (n of isolates) | MLST | Mass (kb) | Inc | Genes co-transferred with *bla*<sub>NDM</sub> |
|--------|---------|---|-------------------------|------|-----------|-----|----------------------------------|
| A      | KSA     | 22 | Hospital A (12) Hospital B (6) Hospital C (4) | ST152 | 110 | NT | *mttC* |
| B      | UAE     | 7  | Kuwait Hospital (2) Qasimi Hospital (5) | ST14 | >170 | H1tb | *bla<sub>CTX-M</sub> or *armA* |
| C      | Oman    | 9  | Royal Hospital (9)      | ST147 | >170 | H1tb | *bla<sub>CTX-M</sub> and *armA* |

NT = nontypable
* in one strain the *ctxM*, in the other one the *armA* gene co-transferred with the NDM plasmid

---

doi:10.1371/journal.pone.0131372.t004
doi:10.1371/journal.pone.0131372.t005
Foreign travel and previous hospitalization

Data on foreign travel during the year before the strains were isolated were available from 150 patients (75.0%) and 23.3% of them had a positive travel history. Sixty per cent of the travel destinations were India, 14.3% Africa, 8.6% Pakistan, and 5.7% each of the Middle East, South East Asia or other regions, respectively. Among the patients with NDM, OXA and VIM-expressing strains positive travel history was recorded for 29.3%, 20.0% and 8.3% of the cases, respectively. One hundred and fifteen patients (72.3% of those with records available) had been treated as in-patients during the year preceding current hospitalization. Previous hospitalization had been documented among 67.5%, 78.9% and 83.3% of those from whom strains with the \( \text{bla}_{\text{NDM}} \), \( \text{bla}_{\text{OXA}} \)-48-like or \( \text{bla}_{\text{VIM}} \) genes were isolated, respectively.

Strains isolated from patients who had travelled or had been previously hospitalized were more likely to express the XDR phenotype than other strains. On the other hand the relation with the different carbapenemase types was more mixed (Table 6). The \( \text{bla}_{\text{NDM}} \) gene, as a single carbapenemase gene was more common among strains isolated from patients with a positive travel history, but less frequent among previously hospitalized individuals. The frequencies of the \( \text{bla}_{\text{OXA}} \)-48-like and \( \text{bla}_{\text{VIM}} \) carbapenemase genes showed exactly the opposite trend: they were more common among non-travellers and among previously hospitalized individuals (Table 6). Irrespective of the differences observed, none of these correlations were statistically significant. Data were not available in sufficiently high number for NDM-OXA double positive strains to carry out a similar analysis.

For 95 previously hospitalized patients from Kuwait, Oman and from the UAE the actual location of prior inpatient care was known (Table 7). 78.6% of them had previously been admitted to a hospital in India, 14.3% in Pakistan and 7.1% in Sudan, respectively. From 78.6% of these patients \( \text{bla}_{\text{NDM}} \)-carrying strains were isolated, significantly more (\( P = 0.0087 \)) than from those treated earlier in a domestic hospital. In contrast, OXA-expressing strains were significantly more common among former inpatients of the same hospital (\( P = 0.0059 \)) than of any other hospitals. However, even with this high rate of \( \text{bla}_{\text{NDM}} \) positive isolates among patients with foreign hospitalization history, records of any recent inpatient care abroad was present in 25.6% of the patients with NDM positive isolates, only. The respective figure was even lower among OXA-48-like isolates (8.1%), and no foreign hospitalization was recorded for any of the cases with VIM-positive strains.

In 69.8% of the 96 CRE cases with all data available no foreign exposure (i.e. neither travel nor foreign hospitalization) could be documented with local figures of 73.7%, 69.8% and 64.3 in Kuwait, Oman and the UAE respectively. No foreign exposure was present in 90.9% and 75.7% of patients infected with VIM and OXA-48-like producing isolates, respectively. Even among those infected with NDM positive strains the complete lack of foreign exposure was as common as 56.8%.

### Table 6. The rate of various carbapenemases in different patient groups.

| Patient groups                  | XDR (%) | NDM (%) | OXA (%) | VIM (%) |
|--------------------------------|---------|---------|---------|---------|
| All with travel data (N = 150)  | 36.7    | 50.0    | 36.5    | 8.0     |
| Travelled (N = 35)              | 45.7    | 62.9    | 31.4    | 2.9     |
| Not travelled (N = 115)         | 33.9    | 46.1    | 38.3    | 9.6     |
| All with hospitalization data   | 38.4    | 50.3    | 35.8    | 7.5     |
| Hospitalized (N = 115)          | 42.6    | 47.0    | 39.1    | 8.7     |
| Non hospitalized (N = 44)       | 27.3    | 59.1    | 27.3    | 4.5     |

<https://doi.org/10.1371/journal.pone.0131372.t006>
Discussion

CRE infections occurring internationally with direct links to the countries of the Arabian Peninsula have been described [21, 24–26, 38, 39] suggesting that the region can serve as source of these strains, just other “reservoir” areas identified earlier do [20]. However, despite the sporadic reports of local cases with no history of travel or foreign hospitalization [4, 5, 7, 9, 29], it has not been known at what rate local cases are likely to be acquired within the borders of the countries of the Peninsula and how these figures relate to the different type of carbapenemases commonly found in the region.

Our results, based on the largest number of strains studied in the region so far, confirmed previous observations [4, 5, 7, 9, 13–15, 28] that currently NDM and OXA-48-like enzymes are the two major carbapenemases of Enterobacteriaceae present in most countries of the Peninsula, albeit with regionally varying proportions (Table 2). The fact that among Kuwaiti isolates blaVIM-4 was the most commonly encountered one was clearly due to the fact that, for comparison, we included strains from a previous study describing a high incidence of VIM-4 in that country [9]. Disregarding this latter subgroup of isolates no further strain expressing this carbapenemase was found and the frequencies of OXA-48-like and NDM enzymes were comparable to those seen in the other countries. It should be noted that while blaVIM-4-carrying strains have also been encountered earlier in the UAE [8] and in the KSA [13, 14], this is the first report on the presence of this carbapenemase type in Oman. NDM-OXA double positive strains, with their comparatively high rate (8.9%) among the UAE isolates have been noted earlier in some of these countries [4, 17, 28]. The fact that in our study these were the isolates most likely to be XDR (Table 4) worth attention.

Regarding the allelic types of the different carbapenemases encountered it was noteworthy that the variant blaNDM-7 detected in two unrelated E. coli strains, (one from the UAE and one from Oman) had already been reported in connection to the Peninsula, i.e. in a strain isolated from a Yemeni patient in Germany [39]. Based on the determination of an internal sequence characteristic to the most common OXA-48-like alleles [36], one of our Omani isolates carried a gene consistent with the respective sequence of the blaOXA-181 variant, i.e. an allele repeatedly described earlier in the same country [4, 6]. As far as we are aware of, neither the blaOXA-162 nor the blaOXA-232 allele have been reported earlier from the Arabian Peninsula.

The apparent absence of KPC-producing strains in the Arabian Peninsula is a particularly interesting observation. While outbreaks have been documented in other parts of the Middle East [40], from countries of the Peninsula this carbapenemase had only been reported once before in an E. coli ST131 strain [41], and recently by us in two K. pneumoniae isolates from...
the UAE [29]. Further studies should reveal whether the apparent local rarity of this carbapenemase, otherwise broadly spread globally, is a temporary, incidental phenomenon, only or it reflects yet to identified specifics of local antibiotic usage or other factors of public health. Similarly, further investigations are needed to clarify whether the notably higher rate of XDR strains (66.0%) in the UAE (Table 4) is a finding biased by the relatively small number of isolates studied or it is a result of differences in local therapy guidelines and practices. Regrettfully, such data were not available to us to compare them with the respective susceptibility figures.

It was also noteworthy, that while having the lowest rate of XDR strains (Table 4), the highest frequency of colistin resistance was found in the KSA collection, a phenomenon well known in that country [42]. Importantly, this was due to sporadic isolates, as only one strain of the 22-member sized cluster A of Saudi isolates exhibited resistance to colistin (data not shown).

The frequent association of 16S methylase-coding genes with plasmids coding for carbapenemases, particularly for \( \text{bla}_{\text{NDM}} \), has been known [43, 44] and our data support that observation. Their wide-spread nature and their highly significant association of these genes with the \( \text{bla}_{\text{NDM}} \)-carrying plasmids are important factors in limiting the therapeutic options for these infections.

We are not aware of previous reports from this region on strains similar to those of the Saudi clone A of the current study (Table 5). On the other hand, an ST14 \( K. \ pneumoniae \) strain, similar to those in Emirati clone B carrying a >170 kb plasmid with \( \text{bla}_{\text{NDM-1}} \) and \( \text{armA} \) genes, had earlier been detected in Oman [5]. While the NDM plasmid in that isolate belonged to a different, i.e. IncL/M incompatibility group, a similar strain isolated in the UAE with a plasmid of the same, i.e. HI1b, incompatibility type was also described [7]. Furthermore, similar IncHI1b plasmids, but in ST147 type strains, had also been reported from Oman [4] and 4 of those strains, together with 6 of our new isolates, formed clone C of the current study. Although transfer of these large, conjugative, IncHI1b NDM plasmids between ST14 (clone B) and ST147 strains (clone C) would offer a plausible explanation for the similarities between episomes of clones B and C, the RFLP did not confirm complete identity of these plasmids (S4 Fig). Further, more detailed analysis of these plasmids is needed to assess the real level of differences between them.

An important finding of this study, shown for the first time, that among CRE infections in the countries of the Arabian Peninsula the lack of foreign exposure is not restricted to a limited number reported previously [4, 5, 7, 9, 11, 12, 28]. In fact, in the majority of the cases (69.8%, varying between 64.3% and 73.7% in the participating countries) we could not demonstrate any history of foreign travel or hospitalization abroad. This finding, contrary to what one may anticipate from the local demography data and from common use of health care abroad, strongly suggests that autochthonous transmission is likely to be a key factor in the epidemiology of CRE in countries of the Peninsula. Although the above statement was true for all CRE types encountered, the lack of foreign exposure was more common for \( \text{bla}_{\text{OXA-48-like}} \) and for \( \text{bla}_{\text{VIM}} \) positive, than for NDM-1 expressing strains. Actually, for strains carrying the latter gene, previous hospitalization abroad (mostly in India in this study) still seems to be a risk factor, even though the majority of such strains (56.7%) still appear to be acquired domestically. Based on these findings it is questionable whether local pre-admission screening criteria can include previous foreign hospitalization/exposure as recommended in several Western countries.

There are several limitations of the current study. Due to criteria by which the current collection of strains was compiled and without the respective data on carbapenem susceptible isolates available, our results does not tell anything about the incidence or prevalence of CRE in the participating countries. Another limitation is that patients had not been screened at
admission, or those results were not available to us. i.e. we do not know whether patients were admitted as carriers or had acquired the strains by nosocomial transmission. Nevertheless, in case of NDM positive isolates, based on the statistically significant correlation, which are in line with previous observations regarding the Indian subcontinent as a frequent source [20, 22, 24, 43], and also on the completely opposite trend seen with OXA-48-like expressing strains, importing NDM-1 positive isolates, mostly from India, is still likely to be an important, albeit not the main contributing factor to the prevalence of these strains in the Arabian Peninsula. The findings also highlight the need for the yet to be developed data on the rate of symptomless carriers of CRE in these communities. The finding that in this study 14.0% of all CRE were E. coli is of high relevance, as representatives of this species are more likely to colonize the gut efficiently and spread the problem outside of the hospitals.

Taken together, the high rate of local transmission suggested by our data, along with the extensive and fast-developing links of these countries to the rest of the world predict that in the future local trends may increasingly impact the global epidemiology of CRE. Only extensive, improved national surveillance strategies combined with close cooperation between countries of the region and beyond carry the promise to contain this fast emerging problem globally and in the countries of the Arabian Peninsula.

Supporting Information

S1 Fig. PFGE dendogram of K. pneumoniae strains. PFGE clusters (≥3 members) are numbered (1–6) and boxed. PFGE clusters marked by dashed lines were not considered “clones” as either not having more than 3 members expressing the same carbapenemases (clusters 2 and 4) or exhibiting variable plasmid profiles and having the same carbapenemase gene located of plasmids of different sizes (cluster 4). Clusters marked by continuous lines were considered clones A–C. The 80% similarity threshold is marked by a horizontal dotted line. * Indicates strains from [9] and ‡ marks isolates from [4].

S2 Fig. PFGE dendogram of E. coli strains. The 80% similarity threshold is marked by a horizontal dotted line. * Indicates strains from [9] and ‡ marks isolates from [4].

S3 Fig. PFGE dendogram of E. cloacae strains. The 80% similarity threshold is marked by a horizontal dotted line. * Indicates strains from [9].

S4 Fig. Restriction fragment length polymorphism patterns of the plasmids from the Omani and Emirati clones. M: Lambda HindIII digest molecular mass standard. A and B: UAE strains ABC119 and ABC130. C and D: Omani strains OM34 and No.2. Panel 1: XbaI; Panel 2: BamHI; Panel 3: Smal digests.

S1 Table. Antibiotic susceptibility of pNDM transconjugants. & Minimal inhibitory concentration, microdilution method. ¶ Disc diffusion. ETP—ertapenem, MEM—meropenem, IMI—imipenem, CAZ—ceftazidime, CTX—cefotaxime, AZT—aztreonam, CIP—ciprofloxacin, GM—gentamicin, AM—aminoglycosides, TO—tobramycin, CHL—chloramphenicol, DOX—doxycycline, TMP-SMX—trimethoprim-sulphamethoxazole, WT—wild type, TC—transconjugant, R—Recipient. * strain identical to isolate No.2 in [4].
Acknowledgments

The dedicated work of the technical staff in the participating hospital laboratories while collecting the isolates is highly appreciated.

Author Contributions

Conceived and designed the experiments: ÁS RH WJ VOR AMS AAJ SSAA SW TP. Performed the experiments: ÁS AAG WJ AAJ WUZT SW TP. Analyzed the data: ÁS AKG AAG RH WJ VOR AMS AAJ SSAA WUZT SW TP. Contributed reagents/materials/analysis tools: ÁS WJ AMS AAJ WUZT TP. Wrote the paper: ÁS SW TP.

References

1. UAEinteract. UAE, Qatar have highest expat ratio in GCC. 2013. Available: http://www.uaeinteract.com/docs/UAE,_Qatar_have_highest_expat_ratio_in_GCC/57040.htm. Accessed 2014 May 5.
2. Al-Qadheeb NS, Althawadi S, Alkhalaf A, Hosaini S, Alrajhi AA. Evolution of tigecycline resistance in *Klebsiella pneumoniae* in a single patient. Ann Saudi Med. 2010; 30(5): 404–407. doi:10.4103/0256-4947.7087 PMID: 20997161
3. Balkhy HH, El-Saed A, Al Johani SM, Francis C, Al-Qahtani AA, Al-Ahdal MN, et al. The epidemiology of the first described carbapenem-resistant *Klebsiella pneumoniae* outbreak in a tertiary care hospital in Saudi Arabia: how far do we go? Eur J Clin Microbiol Infect Dis 2012; 31: 1901–1909. doi:10.1007/s10096-011-1519-0 PMID: 20697161
4. Dortet L, Poirel L, Al Yaqoubi F, Nordmann P. NDM-1, OXA-48 and OXA-181 carbapenemase-producing *Enterobacteriaceae* in Sultanate of Oman. Clin Microbiol Infect. 2012; 18(5): E144–148. doi:10.1111/j.1469-0691.2012.03796.x PMID: 22404169
5. Poirel L, Al Maskari Z, Al Rashdi F, Bernabeu S, Nordmann P. NDM-1-producing *Klebsiella pneumoniae* isolated in the Sultanate of Oman. The J Antimicrob Chemother. 2011; 66: 304–306.
6. Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F, Poirel L. Characterization of OXA-181, a carbapenem-hydrolysing class D beta-lactamase from *Klebsiella pneumoniae*. Antimicrob Agents Chemother. 2011; 55: 4896–4899. doi:10.1128/AAC.00481-11 PMID: 21768505
7. Sonnevend A, Al Baloushi A, Ghazawi A, Hashmey R, Girgis S, Hamadeh MB, et al. Emergence and spread of NDM-1 producer *Enterobacteriaceae* with contribution of IncX3 plasmids in the United Arab Emirates. J Med Microbiol. 2013; 62: 1044–1050. doi:10.1099/jmm.0.059914-0 PMID: 23579399
8. Sonnevend A, Ghazawi A, Yahfoufi N, Al-Baloushi A, Hashmey R, Mathew M, et al. VIM-4 carbapenemase-producing *Enterobacter cloacae* in the United Arab Emirates. Clin Microbiol Infect. 2012; 18: E494–496. doi:10.1111/1469-0691.12051 PMID: 23078093
9. Jamal W, Rotimi VO, Albert MJ, Khodakhast F, Udo EE, Poirel L. Emergence of nosocomial New Delhi metallo-beta-lactamase-1 (NDM-1)-producing *Klebsiella pneumoniae* in patients admitted to a tertiary care hospital in Kuwait. Int J Antimicrob Agents. 2012; 39: 183–184. doi: 10.1016/j.ijantimicag.2011.10.002 PMID: 2213192
10. Ahn C, Butt AA, Rivera JL, Yaqoob M, Hag S, Khalil A, et al. OXA-48-Producing *Enterobacteriaceae* Causing Bacteremia, United Arab Emirates. International journal of infectious diseases. Int J Infect Dis. 2015; 30: 36–37. doi: 10.1016/j.ijid.2014.11.008 PMID: 25462183
11. Al-Agamy MH, Shibi AM, Elkhizzi NA, Meunier D, Turton JF, Livermore DM. Persistence of *Klebsiella pneumoniae* clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. Diagn Microbiol Infect Dis. 2013; 76(2): 214–216. doi: 10.1016/j.diagmicrobio.2013.02.006 PMID: 23518186
12. Marie MA, John J, Krishnappa LG, Gopalkrishnan S. Molecular characterization of the beta-lactamases in *Escherichia coli* and *Klebsiella pneumoniae* from a tertiary care hospital in Riyadh, Saudi Arabia. Microbiol Immunol. 2013; 57: 805–810. doi: 10.1111/j.1348-0421.2012.12104.x PMID: 24117831
13. Shibi A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. The emergence of OXA-48- and NDM-1-positive *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. Int J Infect Dis. 2013; 17: e1130–1133. doi: 10.1016/j.ijid.2013.06.016 PMID: 24021566
14. Zaman TU, Aldrees M, Johani SM, Alothaiman M, Aldughashem FA, Balkhy HH. Multi-drug carbapenem-resistant *Klebsiella pneumoniae* infection carrying the OXA-48 gene and showing variations in...
outer membrane protein 36 resulting in an outbreak in a tertiary care hospital in Riyadh, Saudi Arabia. Int J Infect Dis. 2014; 28: 186–192. doi: 10.1016/j.ijid.2014.05.021 PMID: 25245001

16. Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. beta-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 2013; 26: 361–380. doi: 10.1128/CMR.00096-12 PMID: 23824364

17. Zowawi HM, Sartor AL, Balkhy HH, Walsh TR, Al Johani SM, AlJindan RY, et al. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers. Antimicrob Agents Chemother. 2014; 58: 3085–3090. doi: 10.1128/AAC.02050-13 PMID: 24637692

18. Memish ZA, Assiri A, Almasri M, Roshdy H, Hathout H, Kaase M, et al. Molecular Characterization of Carbapenemase Production Among Gram-Negative Bacteria in Saudi Arabia. Microb Drug Resist. 2015. Ahead of print doi: 10.1089/mdr.2014.0121

19. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. BioMed Res Int. 2014; Article ID 249856, doi: 10.1155/2014/249856

20. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014; 20: 821–830. doi: 10.1111/1469-0691.12719 PMID: 24930781

21. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveillance 2013; 18(31):pii = 20549. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20549.

22. Berrazeg M, Diene S, Medjahed L, Parola P, Drissi M, Raoult D, et al. New Delhi Metallo-beta-lactamase around the world: an eReview using Google Maps. Euro Surveillance: 2014; 19(20):pii = 20809. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20809.

23. Göttig S, Pfeifer Y, Wichelhaus TA, Zacharowski K, Bingold T, Averhoff B, et al. Global spread of New Delhi metallo-β-lactamase 1. The Lancet Inf Dis 2010; 10: 828–829.

24. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013; 62: 499–513. doi: 10.1099/jmm.0.052555-0 PMID: 23329317

25. Mathers AJ, Hazen KC, Carroll J, Yeh AJ, Cox HL, Bonomo RA, et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol. 2013; 51: 680–683. doi: 10.1128/JCM.02580-12 PMID: 23175248

26. Poirel L, Carbonnelle E, Bernabeu S, Gutmann L, Rotimi V, Nordmann P. Importation of OXA-48-producing Klebsiella pneumoniae from Kuwait. J Antimicrob Chemother. 2012; 67:2051–2052. doi: 10.1093/jac/dks167 PMID: 22577102

27. WHO. Antimicrobial resistance: global report and surveillance 2014. Available: http://apps.who.intiris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.

28. Dash N, Panigrahi D, Zarouni MA, Darwish D, Ghazawi A, Sonnevend A, et al. High incidence of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae and Acinetobacter baumannii isolated in Abu Dhabi hospitals. J Med Microbiol. 2013; 62: 582–590. doi: 10.1099/jmm.0.055681-0 PMID: 23264451

29. Sonnevend A, Ghazawi A, Al Munthari N, Pitout M, Hamadheh MB, Hashmey R, et al. Characteristics of epidemic and sporadic strains of Acinetobacter baumannii isolated in Abu Dhabi hospitals. J Med Microbiol. 2013; 62: 5403–5407. doi: 10.1099/jmm.0.05855-11 PMID: 21859933
36. Poirel L. Potron A, Nordmann P. OXA-48-like carbapenemases: the phantome menace. J Antimicrob Chemother. 2012; 67: 1597–1606 doi: 10.1093/jac/dks121 PMID: 22499996
37. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005; 43: 4178–4182. PMID: 16081970
38. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012. J Antimicrob Chemother. 2014; 69: 623–627. doi: 10.1093/jac/dkt433 PMID: 24275115
39. Gottig S, Hamprecht AG, Christ S, Kempf VA, Wichelhaus TA. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-beta-lactamase with increased carbapenemase activity. J Antimicrob Chemother. 2013; 68(8):1737–1740. doi: 10.1093/jac/dkt088 PMID: 23557929
40. Schwaber MJ, Lev B, Israeli A, Solter E, Smolian G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Inf Dis. 2011; 52:848–855.
41. Dashti AA, Vali L, Jadaon MM, El-Shazly S, Amyes SG. The emergence of carbapenem resistance in ESBL-producing Escherichia coli O25B-ST131 strain from community acquired infection in Kuwait. BMC Proceedings. 2011; 5(Suppl 6):O27.
42. Garbati MA, Bin Abdulhak A, Baba K, Sakkijha H. Infection due to colistin-resistant Enterobacteriaceae in critically-ill patients. J Inf Develop Countries. 2013; 7:713–719.
43. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Inf Dis. 2011; 17: 1791–1798.
44. Rahman M, Shukla SK, Prasad KN, Ovejero CM, Pati BK, Tripathi A, et al. Prevalence and molecular characterisation of New Delhi metallo-beta-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India. Int J Antimicrob Agents. 2014; 44: 30–37. doi: 10.1016/j. ijantimicag.2014.03.003 PMID: 24831713